Fig. 1 · Structure

Documents & Downloads

Celecoxib

Cat. No. A10193 CAS 169590-42-5

COX-2 inhibitor

Celecoxib is a sulfa non-steroidal anti-inflammatory drug (NSAID) and selective COX-2 inhibitor used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and to reduce numbers of colon and rectum polyps in patients with familial adenomatous polyposis.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Celecoxib inhibited prostaglandin formation in a purified-enzyme assay, with IC50 values of 0.05 ± 0.03 μM for human recombinant COX-2 and 30.0 ± 15.3 μM for ovine COX-1 (N=3; mean ± SD). Potency depended on enzyme species and assay conditions; this comparison does not measure selectivity between two human isoforms. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
COX-2 (Sf9 cells) 40 nM

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 11.04 μM Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay [PMID: 30877972]
A549 IC50 15.6 μM Antitumor activity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay [PMID: 23353741]
A549 IC50 15.64 μM Antiproliferative activity against human A549 cells after 24 hrs by MTT assay [PMID: 27349331]
A549 IC50 16.08 μM Antiproliferative activity against human A549 cells after 48 hrs by MTT assay [PMID: 30031652]
A549 IC50 17.5 μM Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay [PMID: 32485532]
A549 IC50 2.15 μM Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay [PMID: 26346367]
A549 IC50 57.87 μM Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay [PMID: 35134642]
A549 IC50 7.68 μM Antiproliferative activity against human A549 cells after 48 hrs by MTT assay [PMID: 28720504]
B16-F10 IC50 13.27 μM Antiproliferative activity against mouse B16F10 cells incubated for 48 hrs by MTT assay [PMID: 30877972]
B16-F10 IC50 14.36 μM Antiproliferative activity against mouse B16F10 cells after 24 hrs by MTT assay [PMID: 27349331]
B16-F10 IC50 19.15 μM Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay [PMID: 30031652]
B16-F10 IC50 4.56 μM Antiproliferative activity against mouse B16F10 cells after 24 hrs by MTT assay [PMID: 25866240]
B16-F10 IC50 85.6 μM Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT colorimetric assay [PMID: 22000948]
B16-F10 IC50 85.9 μM Antitumor activity against mouse B16F10 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay [PMID: 23353741]
C6 IC50 > 40 μM Antiproliferative activity against rat C6 cells assessed as growth inhibition incubated for 72 hrs by CCK-8 assay [PMID: 34091208]
Caco-2 IC50 42.74 μM Antiproliferative activity against human Caco2 cells by MTT assay [PMID: 30216848]
CHO IC50 0.036 μM Inhibition of COX2 expressed in CHO cells assessed as inhibition of arachidonic acid-stimulated PGE2 production by enzyme immunoassay [PMID: 15566290]
CHO IC50 13.5 μM Inhibition of COX1 expressed in CHO cells assessed as inhibition of arachidonic acid-stimulated PGE2 production by enzyme immunoassay [PMID: 15566290]
DU-145 IC50 59.34 μM Cytotoxicity against human DU-145 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay [PMID: 35134642]
HCT-116 IC50 29.54 μM Antiproliferative activity against human HCT116 cells by MTT assay [PMID: 30216848]

20 records · Scroll to view more

Celecoxib Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Celecoxib from 3 published references. In vitro models include U251 glioblastoma and BxPc-3 pancreatic carcinoma cells.

Celecoxib In Vitro Studies

In U251 glioblastoma and BxPc-3 pancreatic carcinoma cells, 50 μM celecoxib reduced MTT growth/survival signal and survivin protein. Several other COX inhibitors had little effect at 100 μM, and the distinct analog DMC also reduced these endpoints. The comparison supports additional cellular actions but does not establish survivin as a direct celecoxib target; the Figure 3 exposure duration was unspecified. [2]

COX inhibition measured by LC-MS/MS

Biochemical assay · Purified ovine COX-1 and ovine COX-2; human recombinant COX-2 [1]

Celecoxib inhibited human COX-2 more potently than the ovine enzymes. The selected numerical endpoints are human COX-2 and ovine COX-1; the disputed ovine COX-2 IC50 is omitted. No human COX-1 was tested.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of human recombinant COX-2-dependent PGE2 formationIC50 0.05 ± 0.03 μM (N=3; standard deviation)[1]
Inhibition of ovine COX-1-dependent PGE2 formationIC50 30.0 ± 15.3 μM (N=3; standard deviation)[1]

Literature-Reported Treatment Conditions

Treatment concentration
12 inhibitor concentrations; exact series not tabulated. Arachidonic acid: 5 μM.
Exposure duration
10 min inhibitor preincubation at 37°C; 2 min substrate reaction.
Method
PGE2 formation relative to inhibitor-free DMSO control, quantified by LC-MS/MS.
Vehicle
DMSO; 2 μL added to 200 μL reaction.
Reported limits
Compound purity and lot identity not reported in the retrieved Materials section. Ovine COX-2 numerical discrepancy remains unresolved.
Methods and source locations

Compound reported in the paper: Celecoxib

Reported material and model only; no validation of Adooq lots or equivalence of formulations.

Sections 2.1–2.3 and 3.1–3.2; Table 1; Figure 5

Inhibition of human recombinant COX-2-dependent PGE2 formation: Twelve concentrations each assayed three times; curve fitting of LC-MS/MS PGE2 inhibition. — Table 1 celecoxib row; Figure 5 upper panel; section 2.2

Inhibition of ovine COX-1-dependent PGE2 formation: Same assay design and inhibitor-free DMSO comparison as human COX-2. — Table 1 celecoxib row; Figure 5 lower-right panel; section 2.2

Tumor-cell growth and survivin response

Cell-based study · U251 glioblastoma and BxPc-3 pancreatic carcinoma cells [2]

Celecoxib reduced the MTT growth/survival signal and survivin protein in both models. Other tested NSAIDs/coxibs had little effect at 100 μM; DMC also produced effects. These comparisons support a cellular action beyond a simple shared COX-inhibitor response, but do not establish survivin as a direct binding target or prove that its loss causes cell death.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MTT growth/survival signal and survivin protein abundanceQualitative comparison Reduced with celecoxib in both models; other tested inhibitors at 100 μM had little effect.[2]

Literature-Reported Treatment Conditions

Treatment concentration
Celecoxib 50 μM; DMC 40 μM; valdecoxib, flurbiprofen, indomethacin, sulindac and rofecoxib 100 μM.
Exposure duration
Figure 3 assay duration is not specified in its caption or corresponding MTT/immunoblot methods.
Method
Parallel MTT assay and survivin immunoblot with actin loading control; untreated and DMSO controls.
Vehicle
DMSO; final solvent concentration below 0.5%.
Reported limits
Do not transfer the 48 h exposure from Figure 1 to Figure 3. Figure 3 does not specify replicate number or error-bar semantics; no numerical effect size is extracted.
Methods and source locations

Compound reported in the paper: Celecoxib

Reported material and model only; no validation of Adooq lots or equivalence of formulations.

Results: Down-regulation of survivin is independent of cyclooxygenase-2; Figure 3; Materials and methods

MTT growth/survival signal and survivin protein abundance: MTT and Western blot; actin and untreated/DMSO controls shown. Immunoblots were repeated at least once according to shared methods; no exact percentage inferred from bars. — Figure 3 top/bottom panels and corresponding Results; Materials: Immunoblots and antibodies; MTT assay

Celecoxib In Vivo Studies

In male Holtzman rats, a commercial celecoxib capsule suspension given subcutaneously before paw inflammation prevented mechanical hyperalgesia. Hypoalgesia was strongest at 12 mg/kg and absent at 30 mg/kg. Edema was unchanged at 3–12 mg/kg and reduced at 30 mg/kg; 12 mg/kg did not significantly alter responses in noninflamed saline-injected paws. These findings are specific to this formulation and model. [3]

Systemic celecoxib in rat inflammatory pain

Animal study · Male Holtzman rats; carrageenan-induced paw inflammation; mechanical nociceptive threshold and paw volume [3]

Systemic celecoxib prevented hyperalgesia, with a nonmonotonic hypoalgesic response. Pain-threshold effects occurred at doses without edema reduction. A saline-only control showed no significant effect of 12 mg/kg celecoxib.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Mechanical nociceptive threshold and paw edemaAUC over 4 h Hyperalgesia prevented at 3–30 mg/kg; hypoalgesia maximal at 12 mg/kg and absent at 30 mg/kg; edema unchanged at 3–12 mg/kg, reduced at 30 mg/kg.[3]
Nociceptive threshold and paw volume after saline paw injectionControl comparison No significant difference between celecoxib 12 mg/kg and vehicle at any tested time (0–4 h).[3]

Conditions shared by the study groups

Route
Subcutaneous
Frequency
Single pretreatment
Treatment course
30 min before inflammatory stimulus; Figure 3 summarizes the 0–4 h response.
Vehicle
Physiological saline suspension of commercial Celebra capsule content; dose based on labeled active ingredient.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Celecoxib dose series and noninflamed control
3, 6, 12 and 30 mg/kg (Figure 3); 6 mg/kg time course in Figure 2; 12 mg/kg saline-only control in Table 1.
Corresponding vehicle; contralateral saline-injected paw; Table 1 separate noninflamed paws receiving celecoxib or saline vehicle.Hyperalgesia prevented across the dose range; hypoalgesia most marked at 12 mg/kg and lost at 30 mg/kg. Edema was unchanged at 3–12 mg/kg and reduced at 30 mg/kg. No significant effect in saline-only paws at 12 mg/kg.[3]
Celecoxib dose series and noninflamed control
Model: Male Holtzman rats, 150–200 g; carrageenan-inflamed hind paw and contralateral saline paw. Separate saline-only controls in Table 1.
Reported limits: Figure 3 group-specific n is not stated; Statistics gives n ≥4 per group. Table 1 uses six animals per group. Excipients were present; pure celecoxib equivalence was not tested.
Methods and source locations

Compound reported in the paper: Celecoxib

Reported material and model only; no validation of Adooq lots or equivalence of formulations.

Methods; Figures 2–3; Table 1; corresponding Results and Discussion

Mechanical nociceptive threshold and paw edema: Trapezoidal AUC; means ± SEM; general n ≥4 per group. Figure 3 marks P<0.05 comparisons with carrageenan control and zero threshold difference. No exact AUC values extracted. — Figure 3a–b; dose-response Results; Statistics

Nociceptive threshold and paw volume after saline paw injection: Means ± SEM from six rats per group; subcutaneous pretreatment 30 min before saline paw injection. — Table 1 image and footnote

Celecoxib dose series and noninflamed control · Methods: Pre-treatment with COX inhibitors, Materials, Statistics; Figures 2–3; Table 1 image and footnote

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 169590-42-5
Applications COX-2 inhibitor
Formula C17H14F3N3O2S
Molecular Weight 381.4
Synonyms Celebrex; Celebra
SMILES
CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 65 mg/mL (170.44 mM)
Water Insoluble
Ethanol 28 mg/mL (73.42 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
4 mg/mL
Vehicle
2% DMSO+30% PEG 300+5% Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Celecoxib Research References

  1. [1] Cao H, Yu R, Tao Y, et al. Measurement of cyclooxygenase inhibition using liquid chromatography-tandem mass spectrometry Journal of pharmaceutical and biomedical analysis (2011). PMID: 20817448 DOI: 10.1016/j.jpba.2010.08.001 Source material
  2. [2] Pyrko P, Soriano N, Kardosh A, et al. Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo Molecular cancer (2006). PMID: 16707021 DOI: 10.1186/1476-4598-5-19 Source material
  3. [3] Francischi JN, Chaves CT, Moura AC, et al. Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation British journal of pharmacology (2002). PMID: 12411415 DOI: 10.1038/sj.bjp.0704937 Source material

Added to your cart

View Cart Checkout
Loading...